RxDoctor Payments DataLook up a doctor →

Kathleen Hudson

Nurse Practitioner · Millville, DENPI 1881118420

Payments from drug & device makers

$10,254in general payments, 2019–2025

Across 450 payments — averaging $22.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$958
  • Johnson & Johnson$919
  • QOL Medical, LLC$667
  • AstraZeneca$653
  • GSK$631
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$10,15499%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,254 in reported general payments places this provider in the 95th percentile of 487 nurse practitioner providers in Delaware.

See all nurse practitioner providers in Delaware

Medicare billing

Part B allowed, 2024
$91,792
Medicare patients
653
Services billed
1,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase26$58,989
OzempicSemaglutide16$22,923
JardianceEmpagliflozin20$22,022
FarxigaDapagliflozin Propanediol12$10,452
TrintellixVortioxetine Hydrobromide14$8,325
ClenpiqSod Picosulf/Mag Ox/Citric Ac47$7,995
SutabSod Sulf/Pot Chloride/Mag Sulf40$6,429
Omeprazole237$4,442
Dexlansoprazole DrDexlansoprazole13$3,544
Famotidine202$3,541
Pantoprazole Sodium140$2,626
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C17$2,284
Esomeprazole Magnesium31$2,228
Colesevelam Hcl16$1,794
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl129$1,678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$1,434$58,98926 claims
Novo NordiskOzempic$958$22,92316 claims
Boehringer IngelheimJardiance$240$22,02220 claims
AstraZenecaFarxiga$653$10,45212 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$55$8,32514 claims
Ferring Pharmaceuticals Inc.Clenpiq$46$7,99547 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$201$2,28417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 487 nurse practitioner providers in Delaware.

Other nurse practitioner in Millville

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →